|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Anemia and inflammatory bowel diseases显示文摘Too often anemia is considered a rare or unimportant manifestation in inflammatory bowel disease (IBD). However, over the last 10 years a number of studies have been conducted and the most relevant conclusions obtained are: (1) anemia is quite common in IBD; (2) although in many cases anemia parallels the clinical activity of the disease, many patients in remission have anemia, and iron, vitamin B12 and/or folic acid deficiency; (3) anemia, and also iron def iciency without anemia, have important consequences in the clinical status and quality of life of the patient; (4) oral iron can lead to gastrointestinal intolerance and failure of treatment; (5) intravenous iron is an effective and safe way to treat iron deficiency; (6) erythropoietin is needed in a significant number of cases to achieve normal hemoglobin levels. Thus, the clinician caring for IBD patients should have a comprehensive knowledge of anemia, and apply recently published guidelines in clinical practice. | Fernando Gomollón Javier P Gisbert | 2009 | World Journal of Gastroenterology2009，15，37： | 8 |
| 2 | Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease显示文摘Misconceptions are common in the care of patients with inflammatory bowel disease(IBD).In this paper,we state the most commonly found misconceptions in clinical practice and deal with the use of 5-aminosalicylates and thiopurines,to review the related scientificevidence,and make appropriate recommendations.Prevention of errors needs knowledge to avoid making such errors through ignorance.However,the amount of knowledge is increasing so quickly that one new danger is an overabundance of information.IBD is a model of a very complex disease and our goal with this review is to summarize the key evidence for the most common daily clinical problems.With regard to the use of 5-aminosalicylates,the best practice may to be consider abandoning the use of these drugs in patients withsmall bowel Crohn's disease.The combined approach with oral plus topical 5-aminosalicylates should be the first-line therapy in patients with active ulcerative colitis;once-daily treatment should be offered as a first choice regimen due to its better compliance and higher efficacy.With regard to thiopurines,they seem to be as effective in ulcerative colitis as in Crohn's disease.Underdosing of thiopurines is a form of undertreatment.Thiopurines should probably be continued indefinitely because their withdrawal is associated with a high risk of relapse.Mercaptopurine is a safe alternative in patients with digestive intolerance or hepatotoxicity due to azathioprine.Finally,thiopurine methyltransferase(TPMT)screening cannot substitute for regular monitoring because the majority of cases of myelotoxicity are not TPMT-related. | Javier P Gisbert María Chaparro Fernando Gomollón | 2011 | World Journal of Gastroenterology2011，17，30： | 8 |
| 3 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: Special situations显示文摘 | Gert Van Assche Axel Dignass Bernd Bokemeyer Silvio Danese Paolo Gionchetti Gabriele Moser Laurent Beaugerie Fernando Gomollón Winfried H?user Klaus Herrlinger Bas Oldenburg Julian Panes Francisco Portela Gerhard Rogler Jürgen Stein Herbert Tilg Simon Tra | 2012 | Journal of Crohn’s and Colitis2012，，： | 4 |
| 4 | Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases显示文摘Allogeneic blood transfusion (ABT) is frequently used as the first therapeutic option for the treatment of acute anaemia in patients with inflammatory bowel disease (IBD), especially when it developed due to gastrointestinal or perioperative blood loss, but is not risk-free. Adverse effects of ABT include, but are not limited to, acute hemolytic reaction (wrong blood or wrong patient), febrile non-hemolytic transfusional reaction, bacterial contamination, transfusion-related acute lung injury, transfusion associated circulatory overload, transfusion-related immuno-modulation, and transmission of almost all infectious diseases (bacteria, virus, protozoa and prion), which might result in increased risk of morbidity and mortality. Unfortunately, the main physiological goal of ABT, i.e. to increase oxygen consumption by the hypoxic tissues, has not been well documented. In contrast, the ABT is usually misused only to increase the haemoglobin level within a f ixed protocol [mostly two by two packed red blood cell (PRC) units] independently of the patient' s tolerance to normovolemic anaemia or his clinical response to the transfusion of PRC units according to a 'one-by-one' administration schedule. Evidencebased clinical guidelines may promote best transfusion practices by implementing restrictive transfusion protocols, thus reducing variability and minimizing the avoidable risks of transfusion, and the use of autologous blood and pharmacologic alternatives. In this regard, preoperative autologous blood donation (PABD) consistently diminished the frequency of ABT, although its contribution to ABT avoidance is reduced when performed under a transfusion protocol. In addition, interpretation of utility of PABD in surgical IBD patients is hampered by scarcity of published data. However, the role of autologous red blood cells as drug carriers is promising. Finally, it must be stressed that a combination of methods used within wellconstructed protocols will offer better prospects for blood conservation in selected IBD patients undergoing elective surgery. | José Antonio García-Erce Fernando Gomollón Manuel Muoz | 2009 | World Journal of Gastroenterology2009，15，37： | 3 |
| 5 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management显示文摘 | A. Dignass G. Van Assche J.O. Lindsay M. Lémann J. S?derholm J.F. Colombel S. Danese A. D’Hoore M. Gassull F. Gomollón D.W. Hommes P. Michetti C. O’Morain T. ?resland A. Windsor E.F. Stange S.P.L. Travis | 2010 | Journal of Crohn’s and Colitis2010，，1： | 2 |
| 6 | Use of agents stimulating erythropoiesis in digestive diseases显示文摘Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron def iciency in IBD. There is also a variable component of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin (rHuEPO), which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as f irst choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit (11-12 g/dL). New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same eff icacy and safety. | Rosario Moreno López Beatriz Sicilia Aladrén Fernando Gomollón García | 2009 | World Journal of Gastroenterology2009，15，37： | 2 |
| 7 | Current Management of Iron Deficiency Anemia in Inflammatory Bowel Diseases: A Practical Guide显示文摘 | Fernando Gomollón Javier P. Gisbert | 2013 | Drugs2013，，16： | 2 |
| 8 | Anemia and digestive diseases: An update for the clinician显示文摘Anemia and iron deficiency are so common in digestive diseases that often are underestimated and undertreated. Our goal is to review from classif ication to treatment of the diverse types of anemias in different digestive diseases to update our knowledge on diagnosis and treatment. With the goal of improving the prognosis and quality of life of digestive diseases patients, we will review current transfusion, intravenous iron, and erythropoietin roles in the treatment of anemia. | Fernando Gomollón Javier P Gisbert | 2009 | World Journal of Gastroenterology2009，15，37： | 2 |
| 9 | Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol显示文摘 | Antonaccio MJ Gomoll A | 1993 | Am J Cardiol1993，72，： | 1 |
| 10 | Use of a type IAII bilayer collagen membrane decreases ropcmtion rates for symptomatic hypertrophy after autoiogous chondrocyte implantation 显示文摘 | Gomoll AH Probst C Fan: J | 2009 | Am J Sports Med2009，371，： | 1 |
| 11 | Therapeutic guidelines on ulcerative colitis:a GRADE methodology based effort of GETECCU显示文摘 | Gomollón F García-López S Sicilia B | | 0，，02： | 1 |
| 12 | Biomechanical considerationsin the pathogenesis of osteoarthritis of the knee显示文摘 | Heijink A Gomoll A H Madry H | 2011 | Knee Surg SportsTraumatol Arthrosc2011，20，3： | 1 |
| 13 | Increased fhil- ure rate of autologous chondrocyte implantation after previ- ous treatment with marrow stimulation techniques 显示文摘 | Minas T Gomoll AH Rosenberger R | 2009 | Am J Sports Med2009，37，5： | 1 |
| 14 | 骨科教程膝关节软骨缺损的手术处理显示文摘关节软骨缺损在膝关节镜手术中十分常见。如若伴有症状出现,其对膝关节功能的影响堪与晚期骨性关节炎相比。 | A.H. Gomoll, MD J. Farr, MD S.D. Gillogly, MD J. Kercher, MD T. Minas, MD, MS 罗浩(译) 郭秦炜(译) 杨渝平(译) 敖英芳(译) 李拉(译) 蒋艳芳(译) | 2011 | 中华骨科杂志2011，31，3： | 1 |
| 15 | Microfracture and augments显示文摘 | Gomoll AH | 2012 | J Knee Surg2012，25，1： | 1 |
| 16 | Use of a type I/III bilayer collagen membrane decreases reoperation rates for symptomatic hypertrophy after autologous chondrocyte implantation显示文摘 | Gomoll AH Probst C Farr J | | 0，，1： | 1 |
| 17 | Repair and tissue engineering techniques for articular cartilage显示文摘 | Makris EA Gomoll AH Malizos KN | 2015 | Nat Rev Rheumatol2015，11，1： | 1 |
| 18 | The subchondral bone in articular cartilage repair: current problems in the surgical management显示文摘 | Gomoll AH Madry H Knutsen G | 2010 | Knee Surg Sports Traumatol Arthrosc2010，18，4： | 1 |
| 19 | Triad of cartilage restoration for unicompartmental arthritis treatment in young patients:meniscus allograft transplantation,cartilage repair and osteotomy显示文摘 | Gomoll AH Kang RW Chen AL | | 0，，02： | 1 |
| 20 | Disease severity in familial cases of IBD显示文摘 | M. Andreu L. Márquez E. Domènech J.P. Gisbert V. García I. Marín-Jiménez M. Pe?alva F. Gomollón X. Calvet O. Merino E. Garcia-Planella N. Vázquez-Romero M. Esteve P. Nos A. Gutiérrez I. Vera J.L. Cabriada M.D. Martín A. Ca?as-Ventura J. Panés | 2014 | Journal of Crohn’s and Colitis2014，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员